Strategic Growth Fortrea's rapid expansion through acquisitions and asset integration signals ongoing demand for robust clinical development capabilities; target cross-sell with Chiltern’s oncology, anti-infectives/vaccines, ophthalmology, medical device, and diagnostic development services to capture synergies.

Financial Momentum Recent revenue milestones and improved EPS indicate a healthy financial trajectory; approach with value propositions around scalable trial delivery, cost efficiency, and technology-enabled solutions to align with Fortrea’s growth strategy.

Technology Leverage Fortrea’s launch of Intelligent Technology and investment in tech stacks (Azure, analytics, and digital training) create opportunities to position Chiltern’s data-driven, agile trial delivery and digital training capabilities as complementary assets.

Global Reach With a presence in over 90 countries and a large investigator site network, there is a clear opportunity to propose expanded global trial management, local regulatory support, and site optimization services to support multinational programs.

Key Relationships Fortrea leadership engagement with investors and ongoing partnerships indicate a preference for strategic, high-value collaborations; tailor proposals emphasizing joint go-to-market strategies, integration timelines, and measurable performance outcomes.